OncoTargets and Therapy (Jun 2021)
Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review
Abstract
Xin Tian, Qiuxia Zhu, Zhenyong Zhang Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110022, People’s Republic of ChinaCorrespondence: Zhenyong ZhangDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110022, People’s Republic of ChinaEmail [email protected]: Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clinical practice. When and how to effectively treat both tumors, without compounding adverse effects, must be addressed. Herein, we describe an elderly man who presented with both gastric cancer (HER2+) and bladder cancer. Due to enlarged and fused lymph nodal metastasis, he was ill-suited for stomach resection. After transurethral resection of the bladder tumor, we administered both chemotherapy and the targeted agent trastuzumab. Gastric cancer showed partial response however bladder cancer recurred following two cycles of this regimen, the adverse effects were prohibitive, prompting refusal of further chemotherapy and radiotherapy. He then received the immune checkpoint inhibitor (ICI) nivolumab and trastuzumab in combination. This particular regimen successfully controlled both cancers and substantially improved the patient’s quality of life. Its long-term use did not intensify adverse reactions, enabling a progression-free survival of 21 months to date. We have also reviewed other published clinical strategies applied in rare instances of multiple primary malignancies as a reference for treating such patients.Keywords: immunotherapy, targeted therapy, synchronous cancer, HER2-positive gastric cancer, bladder cancer
